Document is current
Any future updates will be listed below
-
Authors
,
Adams, Mark D.
Boileau, Etienne
Bujnicki, Janusz M.
Cheung, Vivian G.
Conticello, Silvestro G.
Dedon, Peter
Dieterich, Christoph
Gallo, Angela
Göke, Jonathan
Helm, Mark
Jantsch, Michael F.
Kaiser, Stefanie
Lee, Charles
Marchand, Virginie
Mortazavi, Ali
Motorin, Yuri
Schwartz, Schraga
Tolbert, Blanton S.
Williamson, James
-
Funding
Funding for this research was provided by:
National Institutes of Health (U24HG011735, ES034919, ES031576)
Deutsche Forschungsgemeinschaft
National Science Center, Poland
Warren Alpert Foundation
National Center for Gene Therapy and Drugs
National Research Foundation of Singapore
Agilent Foundation
Austrian Science Fund (https://doi.org/10.55776/F80)
PRC IDyL ANR (24-CE17-7018)
PRC epiRNA-T2D (ANR-23-CE14-0040)
Howard Hughes Medical Institute
- License Information
-
More Information
Article History
Received: 15 January 2025
Accepted: 30 September 2025
First Online: 24 October 2025
Declarations
:
: Not applicable.
: M.D.A., S.G.C., A.G., M.H., V.M., Y.M., B.S.T., and C.D. declare no competing interests. P.C.D. has founded companies related to RNA modifications and therapeutics. M.H. serves as a consultant for Moderna Inc. and is an inventor on several patents pending related to RNA technology. V.G.C. serves as a scientific founder of an RNA company. M.F.J. has a patent application for site-directed RNA editing.
